Home / Intelligence /

Search

Webinars

Looking Ahead to the November Election and Beyond

August 14, 2024 | 1:00 - 2:00 PM ET

As healthcare policy and the access landscape evolve, biopharma companies face challenges in navigating this ever-changing space. To help organizations prepare for and adapt to these changes, Trinity Life Sciences is offering a new webinar series, The Next Era in U.S. Healthcare Policy & Access.Join us for the first webinar in the series, Looking Ahead to the November Election and Beyond, where Maximilian Hunt, Partner at Trinity, will host an interactive discussion with health policy expert, Lisa Joldersma, Founder and…

Sign Up Now

Blog

Developing Effective Global Value Dossiers 

Published June 13, 2024

Trinity Life Sciences recently worked with a large global pharma company to develop a new process for creating global value dossiers (GVDs) that better met the needs of regional affiliates. Matt O’Hara, who leads Trinity’s Evidence Strategy practice, shares insights into the project with Mary Fletcher-Louis, who recently joined Trinity to head Trinity’s Value Center of Excellence.  Understanding the Challenge  The project involved reviewing the client’s 15 most recent GVDs and scoring each chapter for effectiveness, ease of use, level…

Read Now

Blog

Rise with the Waves: UK – Now and Beyond – Four Policy Trends That May Shape Pharma’s Future 

Published May 23, 2024

Executive Summary The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which are expected to improve patient access while balancing financial healthcare sustainability and overall market attractiveness. A few key developments announced or already implemented include: The shift of the much-debated Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) to…

Read Now

Webinars

HTA Vision—Implications Beyond the Rating

Available On Demand

A number of critical manufacturer activities are informed by understanding health technology assessment (HTA) agency behavior across geographies and therapeutic areas—from pipeline, business development and licensing to launch planning preparation through to lifecycle management strategy. Join Max Hunt, a Partner in Trinity Life Sciences’ Evidence, Value, Access & Pricing Practice, as he hosts a lively discussion on the benefits of rapid access to cumulative, compounded learnings generated from in-depth analysis of global HTA recommendations, with presenters Mary Fletcher-Louis, Managing Director…

Watch Now

Blog

Rise with the Waves: France – Accelerating Pricing and Market Access: Two Policies Shaping Pharma’s Future

Published April 22, 2024

Executive Summary The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to innovate its healthcare system. The 2024 PLFSS emphasizes: Drug access and cost containment, with a higher payback trigger aimed at reducing the government’s payback collections Temporary reimbursement to ensure continuous treatment of patients with medicines benefitting from the early…

Read Now

Webinars

2023 NRDL Update: An Ongoing Voyage of Innovation and Accessibility

Available On Demand

How can manufacturers strategize for pricing and market access success amidst the evolving landscape of China’s NRDL? As China continues to be a key pharmaceutical market, understanding the latest National Reimbursement Drug List (NRDL) trends and policy evolvement is crucial for manufacturers aiming to achieve successful access and pricing outcomes.  In this webinar, a panel of Trinity Life Sciences’ Value, Access and Pricing experts will discuss the role of the new value-based assessment framework in NRDL payer decision-making and dive…

Watch Now

Blog

Rise with the Waves: Canada – A Coming (R)evolution: Transforming Pharmaceutical Market Access

Published April 5, 2024

Executive Summary Canada has undertaken meaningful strategies to transform patient access and ultimately improve health outcomes across the country. Two such potentially high-impact strategies include the planned transformation of the former Canadian Agency for Drugs and Technology in Health (CADTH) into the new Canadian Drug Agency (CDA) over the course of the next five years, as well as the implementation of time-limited reimbursement for specific drugs. While the Canadian Drug Agency is set to advance Canada’s pharmaceutical system by standardizing…

Read Now

Blog

Using Transparency in Coverage Reimbursement Insights to Inform Payer and Provider Contracting Strategy

Published April 5, 2024

Executive Summary “Transparency in Coverage” (TIC) data is a newer data source that has recently become available for mining unique insights in the reimbursement/economics between payers and providers. In 2020, the Federal Government TIC Rule required health insurers and group health plans, including self-funded clients, to provide cost-sharing data to consumers via machine-readable files and a consumer price transparency tool. Beginning July 1, 2022, machine-readable files were published publicly, and include pricing data for covered items and services based on…

Read Now

White Papers

What Is Keeping Community Oncology Providers Up at Night?

Community oncology practices are critical to the delivery of cancer care in the United States, treating about 80%, of patients. (~40% in community clinics and ~40% in community hospitals). Providing top-quality care in the community setting has unique challenges, including keeping pace with the accelerating innovation in cancer care (13 novel drugs and additional 67 indication expansions approvals in 2023 alone) while treating a widely diverse patient population, navigating increasingly complex non-clinical prescribing decision influencing factors (e.g., U.S. managed care…

Read Now

Blog

Rise with the Waves: Italy – AIFA Restructuring and Budget Reforms – Stepping into a New (Uncertain) Future?

Published March 20, 2024

Executive Summary The Italian Medicines Agency (AIFA) underwent transformative changes on January 30, 2024, following a much-anticipated reorganization. AIFA’s restructuring has already faced challenges, with the recent resignation of the newly created Scientific and Economic Commission’s (CSE) chairman followed by the appointment of a new acting chairman, highlighting the need for a stable and collaborative leadership within AIFA.   Although AIFA’s overhaul has been implemented following a year-long delay due to bureaucratic complexities and is currently facing uncertainties, it will be…

Read Now